Pharmaceutical Multi-Facility Registration
How PharmaCorp International streamlined FDA registration across 12 global facilities, reducing compliance costs by over $340,000 annually while improving oversight and consistency.
- 6 Months
- Project Duration
- $340,000
- Annual Savings
- 520%
- Return on Investment
The Client
PharmaCorp International is a global pharmaceutical company specializing in generic medications. With 12 manufacturing facilities across 6 countries and over 500 products in the US market, they faced significant complexity in managing FDA compliance.
Global Footprint
- Facilities:
- 12 manufacturing sites
- Countries:
- India, Germany, Brazil, Mexico, USA, Canada
- US Products:
- 500+ NDCs
- Annual FDA Fees:
- $4.2M (GDUFA)
The Challenge
PharmaCorp's decentralized approach to FDA compliance had led to inefficiencies, inconsistencies, and escalating costs. Each facility managed its own registrations with different local consultants, leading to duplicated efforts and compliance gaps.
Pain Points
- •Inconsistent registration and listing data across facilities
- •Missed renewal deadlines causing registration lapses
- •8 different regulatory consultants with varying quality
- •No centralized view of compliance status
- •GDUFA fee optimization opportunities being missed
The Solution
We implemented a comprehensive centralized compliance program that brought all facilities under unified management:
Phase 1: Assessment and Consolidation (Month 1-2)
- Complete audit of registration status for all 12 facilities under 21 CFR Part 207 (drug establishment registration) and 21 CFR Part 207.33 (product listing requirements). Verified each facility's DUNS number, FEI number, and registration status in FDA's Unified Registration and Listing System (FURLS)
- Inventory of 500+ NDC (National Drug Code) product listings with accuracy verification -- cross-referenced each NDC against the SPL (Structured Product Labeling) submissions on file to identify discrepancies in labeling data, active ingredients, and dosage forms
- Gap analysis identifying 127 inconsistencies and errors including outdated labeling agents, incorrect establishment types, and missing annual product listing updates
- Transition from 8 separate regulatory consultants across 6 countries to a single point of management through Assurentry, eliminating coordination overhead and ensuring consistent quality
Phase 2: Remediation (Month 2-4)
- Corrected all 127 listing errors and inconsistencies through updated SPL submissions to FDA -- each SPL was reviewed for accuracy in active ingredients, dosage forms, routes of administration, and establishment roles
- Standardized data formats across all facilities to ensure consistent FEI/DUNS linkages, establishment type designations, and registration activity codes
- Resolved 3 lapsed registrations before FDA took action -- drug establishment registrations must be renewed annually (October 1 - December 31), and a lapsed registration can trigger FDA enforcement including Warning Letters, import alerts, and product seizure
- Updated US Agent designations for 8 foreign facilities per 21 CFR 207.40, ensuring each foreign establishment had a properly designated US Agent with 24/7 FDA communication capability
Phase 3: Optimization (Month 4-6)
- Implemented centralized compliance dashboard with real-time registration status tracking across all 12 facilities and 500+ products
- Established automated renewal reminders with 90/60/30-day advance notifications for the October-December annual registration window
- Optimized GDUFA (Generic Drug User Fee Act) fee payments through proper facility categorization -- correctly identified 2 facilities as API-only sites qualifying for lower GDUFA self-identified facility fees ($229,070 vs. the finished dosage form rate), saving $45,000 annually
- Created standardized SOPs for global compliance team covering registration maintenance, product listing updates, SPL submission procedures, and US Agent communication protocols
The Results
100% Compliance
All 12 facilities now maintain current, accurate registrations with zero lapses since implementation.
$340K Annual Savings
Reduced compliance management costs through consolidation and fee optimization.
Unified Oversight
Real-time compliance dashboard provides visibility across all facilities and products.
Risk Reduction
Eliminated risk of registration lapses and associated FDA enforcement actions.
Regulatory Framework Applied
- Establishment Registration:
- 21 CFR Part 207 (annual renewal required)
- Product Listing:
- 21 CFR 207.33 (SPL submissions)
- GDUFA Fees:
- Self-Identified Facility: $229,070/yr (FY2026)
- PDUFA Program Fee:
- $417,271/yr per approved NDA/BLA (FY2026)
- US Agent Requirement:
- 21 CFR 207.40 (foreign establishments)
- Registration System:
- FURLS (FDA Unified Registration and Listing System)
Understanding PDUFA and GDUFA Fees
Pharmaceutical companies face two major FDA user fee programs: PDUFA (Prescription Drug User Fee Act) applies to innovator drug companies and charges annual program fees of $417,271 per approved NDA/BLA product. GDUFA (Generic Drug User Fee Act) applies to generic drug manufacturers and charges facility fees based on whether the site produces finished dosage forms or APIs. For companies with multiple facilities like PharmaCorp, proper categorization of each site can yield significant fee savings. GDUFA fees are invoiced annually and must be paid within 30 days -- failure to pay results in facility registration suspension.
Cost Breakdown
| Category | Before (Annual) | After (Annual) | Savings |
|---|---|---|---|
| Consultant fees (8 vendors) | $480,000 | $180,000 | $300,000 |
| Internal coordination overhead | $120,000 | $35,000 | $85,000 |
| GDUFA fee optimization | - | - | $45,000 |
| Avoided registration lapse costs | - | - | $90,000* |
| TOTAL ANNUAL SAVINGS | $600,000 | $215,000 | $520,000 |
*Estimated based on historical lapse frequency and associated costs
Implementation Timeline
Comprehensive audit and gap analysis
Vendor consolidation and transition
Data remediation and standardization
System optimization and training
"Before Assurentry, our FDA compliance was a mess. Different facilities doing things different ways, no central visibility, and we were always worried about missing a deadline. Now we have one partner managing everything, real-time visibility into our compliance status, and we're saving over $300,000 a year. This is exactly how global regulatory compliance should work."
Managing Multi-Facility Compliance?
If you're struggling with compliance across multiple facilities, we can help you centralize, optimize, and reduce costs while improving oversight.